← Leaderboards
Romel D Mackelprang
University Of Washington
$4,761,625
Attributed
$4,761,625
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $774.3K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,761,625 · 3
By mechanism
R01$3,617,007 · 1
K01$641,250 · 1
R21$503,368 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Washington
Same institution · by research overlap
- Michael G Katze$67,933,838
- Stephen J. Polyak$9,333,019
- James Ivan Mullins$34,901,920
- Grace C John-Stewart$42,921,726
- James P Hughes$12,914,045
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsLeadMediatingImmune ResponseImmuneInfectionPlasmaVirusHiv-1ResponsePeripheral Blood Mononuclear CellIn VitroCouplesCellsSamplingCohortRegulationChronicInterferonsHiv InfectionsImmune ActivationGenesBioinformaticsGene Expression
Grant awards (12)
Longitudinal analysis of HIV reservoir and type I/III interferon system in people with HIV who initiated ART during primary infection$220,089
R21 · FY2025 · AI · contact PI
Longitudinal analysis of HIV reservoir and type I/III interferon system in people with HIV who initiated ART during primary infection$283,279
R21 · FY2024 · AI · contact PI
Identification of drug-targetable IFN-stimulated genes mediating immune activation during ART-treated HIV-1 infection$724,753
R01 · FY2022 · AI · contact PI
Identification of drug-targetable IFN-stimulated genes mediating immune activation during ART-treated HIV-1 infection$739,577
R01 · FY2021 · AI · contact PI
Identification of drug-targetable IFN-stimulated genes mediating immune activation during ART-treated HIV-1 infection$749,701
R01 · FY2020 · AI · contact PI
Identification of drug-targetable IFN-stimulated genes mediating immune activation during ART-treated HIV-1 infection$756,974
R01 · FY2019 · AI · contact PI
Identification of drug-targetable IFN-stimulated genes mediating immune activation during ART-treated HIV-1 infection$646,002
R01 · FY2018 · AI · contact PI
CTL mechanisms underlying effects of HLA-A*2301 and B*5301 on HIV-1 set-point$128,250
K01 · FY2018 · AI · contact PI
CTL mechanisms underlying effects of HLA-A*2301 and B*5301 on HIV-1 set-point$128,250
K01 · FY2017 · AI · contact PI
CTL mechanisms underlying effects of HLA-A*2301 and B*5301 on HIV-1 set-point$128,250
K01 · FY2016 · AI · contact PI
CTL mechanisms underlying effects of HLA-A*2301 and B*5301 on HIV-1 set-point$128,250
K01 · FY2015 · AI · contact PI
CTL mechanisms underlying effects of HLA-A*2301 and B*5301 on HIV-1 set-point$128,250
K01 · FY2014 · AI · contact PI